Replimune's RP1 Hits Regulatory Wall as Single-Arm Trial Fails to Meet Established Oncolytic Virus Precedents

FDA Deems Replimune's Melanoma Data "Not Interpretable"

The FDA has deemed Replimune's single-arm mid-stage study for its oncolytic immunotherapy, vusolimogene oderparepvec (RP1), "not interpretable" for accelerated approval in combination with Bristol Myers Squibb’s Opdivo for advanced cutaneous melanoma. This marks the third time the agency has raised significant concerns, setting the stage for a challenging Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting. The FDA cited issues with the response assessment in the IGNYTE study, stating that the objective response data were insufficient and that without a reliable control, RP1's contribution to efficacy could not be determined. Replimune's stock fell over 32% following the release of the negative briefing documents.

• The FDA's primary objection centers on the Phase 1/2 IGNYTE study's single-arm design and its response assessment methodology, which reviewers found "confounds interpretation of the reported efficacy results." Specifically, the agency stated that the objective response data were "not of sufficient magnitude to overcome concerns" about efficacy, and the absence of a reliable historical control made it impossible to determine RP1's contribution when combined with Opdivo. The overall survival analysis was also deemed "not interpretable."
• Replimune countered the FDA's concerns by arguing that a randomized trial would be unethical for this patient population, as anti-PD-1 monotherapy offered no hope for response after progression. The company emphasized that when IGNYTE was conducted, no treatments were available for patients who had progressed post-anti-PD-1, and continuing such therapy was not considered appropriate clinical practice. Replimune also highlighted that the FDA has previously granted approvals based on single-arm studies for melanoma patients, citing examples like Iovance's Amtagvi and Merck's Keytruda.
• The Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) is scheduled to vote on whether IGNYTE's efficacy results are evaluable and clinically meaningful. BMO Capital Markets noted that the panel's composition "skews negatively" for Replimune, anticipating an "uphill battle." Following the release of the FDA's negative briefing documents, Replimune's stock plummeted over 32%, reflecting investor concerns about the drug's approval prospects, despite the possibility that clinicians on the panel might advocate for clinical meaningfulness.

The Critical Unmet Need in Post-PD-1 Advanced Melanoma

Despite the transformative impact of immune checkpoint inhibitors (ICIs) on advanced melanoma, a substantial proportion of patients either do not respond or eventually develop resistance and progress. This has created a critical unmet need for effective therapeutic strategies in the post-PD-1 setting. Consequently, recent research has focused on identifying and treating specific refractory patient populations with novel combinations and treatment sequences.

• Targeting Heavily Pre-treated Patients: Real-world evidence supports the use of anti-PD-1 plus lenvatinib in heavily pretreated patients who have failed prior ICI therapy. One multicenter study of 120 patients—98% of whom had prior ipilimumab/nivolumab treatment—demonstrated an objective response rate (ORR) of 23% and a median overall survival (mOS) of 10 months. A separate study of 67 patients with poor prognostic factors reported a similar ORR of 28.4% and mOS of 9.8 months, suggesting this combination provides meaningful clinical activity in a population with limited options.

• Distinguishing Post-Adjuvant vs. Metastatic Resistance: The MASTERKEY-115 trial, evaluating talimogene laherparepvec (T-VEC) plus pembrolizumab, revealed divergent outcomes based on resistance settings. The combination showed significant antitumor activity in patients who recurred on or after adjuvant anti-PD-1 therapy (ORR of 40-47%). In stark contrast, it was largely ineffective in patients with established metastatic disease who had developed primary or acquired resistance (ORR of 0-7%), underscoring that the timing and nature of resistance are critical for defining target populations.

• Characterizing Hyperprogressive Disease (HPD): HPD represents a distinct clinical challenge in a subset of patients progressing on ICIs. An analysis of 262 patients on anti-PD-1 monotherapy found HPD incidence rates ranging from 10.8% to 28.2%, depending on the definition used. This research identified having more than two metastatic organs as a key risk factor and specifically highlighted mucosal melanoma as a subtype where HPD was particularly prevalent.

• Revisiting Chemotherapy in the Post-ICI Landscape: For patients refractory to multiple lines of immunotherapy, conventional chemotherapy is being re-evaluated as a viable option. A study of patients receiving dacarbazine found that prior exposure to pembrolizumab was associated with significantly improved outcomes. The group pre-treated with pembrolizumab had a longer median progression-free survival (3.9 vs. 2.3 months; p=0.001) and a substantially longer median overall survival (19.0 vs. 6.8 months; p=0.003) compared to ICI-naive patients, suggesting prior immunotherapy may enhance chemosensitivity.

• Addressing High-Risk Subtypes: Mucosal melanoma consistently emerges as an underserved population with a clear unmet need. Compared to cutaneous melanoma, this subtype generally responds less favorably to immune checkpoint inhibition. It has also been identified as a prevalent subtype for developing hyperprogressive disease, highlighting the need for dedicated research and novel therapeutic strategies tailored to this specific patient group.

Navigating the Evolving Treatment Landscape for Advanced Melanoma

Over the past five years, real-world and trial data have consistently underscored that outcomes following anti-PD-1 progression remain suboptimal, even as the field has diversified its therapeutic armamentarium. Among 304 patients progressing on anti-PD-1 therapy, subsequent treatment patterns split across immunotherapy (50%), BRAF/MEK inhibitors (36%), and other approaches (14%), yielding a median overall survival of just 7.2 months. Survival in this setting correlated strongly with baseline response to prior anti-PD-1 therapy, ECOG performance status, LDH normalization, and receipt of BRAF/MEK inhibition. Randomized data further clarified the limited utility of ipilimumab-based rescue strategies: a phase II trial comparing ipilimumab monotherapy versus ipilimumab plus nivolumab in PD-1-refractory patients showed higher response rates with single-agent ipilimumab (55.6% vs. 20%), though disease control and toxicity rates were comparable—reinforcing that dual checkpoint blockade does not reliably overcome PD-1 resistance. Biomarker analyses in this trial linked clinical benefit to increased polyfunctional CD4+ T-cell responses and NRAS-mutant tumors with heightened immune transcriptional activity, pointing toward potential predictive signatures for future patient selection.

Novel combination strategies have since emerged to address this unmet need. Nivolumab-relatlimab (anti-PD-1/anti-LAG-3) has shown improved progression-free survival over nivolumab monotherapy in the first-line setting, with favorable tolerability, and real-world data from a tertiary cancer center reported an ORR of 39%, with particularly strong outcomes in treatment-naïve patients—suggesting durable potential as a first-line option, though its role post-PD-1 progression specifically remains less defined. Oncolytic virotherapy combined with checkpoint inhibition has also demonstrated activity in this refractory population: the MASTERKEY-115 trial of talimogene laherparepvec (T-VEC) plus pembrolizumab showed minimal activity in primary and acquired PD-1 resistance (ORR 0–6.7%), but notably higher response rates (40–46.7%) in patients with resectable disease recurring after adjuvant anti-PD-1 therapy, highlighting a resistance-context-dependent efficacy pattern. Consistent with this, European registry data (EUMelaReg) confirmed that prior adjuvant anti-PD-1 exposure significantly blunts response to subsequent first-line ICI retreatment (ORR 31.4% vs. 48.8% in PD-1-naïve patients), with early recurrence during or shortly after adjuvant therapy predicting particularly poor outcomes (ORR 28.5%, PFS 3.1 months).

Despite these advances, a substantial proportion—up to 50%—of patients with advanced melanoma still derive no meaningful benefit from available immunotherapies, and clinicians continue to lack reliable tools to predict response, durability, or toxicity risk in advance. Investigational approaches explored over this period, including tovorafenib, plozalizumab, and vedolizumab combinations with nivolumab and/or ipilimumab, have largely yielded disappointing results, with early trial termination due to lack of clinical benefit or excessive toxicity (e.g., grade ≥3 adverse events in up to 83.3% of patients in the vedolizumab triplet arm). Emerging modalities such as tumor-infiltrating lymphocyte (TIL) therapy and oncolytic virotherapy show promise, while CAR-T cell approaches remain comparatively unsuccessful in melanoma due to tumor microenvironment and antigen-specificity challenges. Collectively, the data from 2020–2025 reflect a landscape that has expanded mechanistically—incorporating LAG-3 blockade, intralesional therapies, and biomarker-driven trial designs—but has yet to solve the core clinical challenge of durable efficacy after PD-1 progression, reinforcing the field's continued focus on predictive biomarkers, rational combination strategies, and toxicity mitigation.